Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $572.72 Consensus Target Price from Analysts

Posted by Geri Gentry on Jun 20th, 2026

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) have received an average rating of “Moderate Buy” from the twenty-one analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, fourteen have assigned a buy rating and four have assigned a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $566.2105.

PRAX has been the topic of a number of research analyst reports. Wells Fargo & Company set a $305.00 price target on Praxis Precision Medicines and gave the stock an “equal weight” rating in a research report on Friday, February 20th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $374.00 price target (down from $420.00) on shares of Praxis Precision Medicines in a research report on Tuesday, June 2nd. BTIG Research restated a “buy” rating and set a $810.00 price target (down from $843.00) on shares of Praxis Precision Medicines in a research report on Tuesday, June 2nd. Royal Bank Of Canada initiated coverage on Praxis Precision Medicines in a research report on Wednesday. They set an “outperform” rating and a $449.00 price target on the stock. Finally, Wolfe Research initiated coverage on Praxis Precision Medicines in a research report on Monday, February 23rd. They set an “outperform” rating and a $500.00 price target on the stock.

View Our Latest Analysis on Praxis Precision Medicines

Praxis Precision Medicines Stock Performance

PRAX stock opened at $282.31 on Friday. Praxis Precision Medicines has a 1-year low of $37.19 and a 1-year high of $366.52. The firm has a market cap of $7.87 billion, a P/E ratio of -21.12 and a beta of 2.71. The business’s 50 day moving average is $315.29 and its 200-day moving average is $303.42.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($3.20) earnings per share for the quarter, beating the consensus estimate of ($3.58) by $0.38. Sell-side analysts forecast that Praxis Precision Medicines will post -14.79 EPS for the current year.

Institutional Investors Weigh In On Praxis Precision Medicines

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Praxis Precision Medicines by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,267,286 shares of the company’s stock worth $67,166,000 after acquiring an additional 51,642 shares during the last quarter. Algert Global LLC boosted its position in Praxis Precision Medicines by 483.3% in the 3rd quarter. Algert Global LLC now owns 160,818 shares of the company’s stock valued at $8,523,000 after buying an additional 133,248 shares during the last quarter. Rafferty Asset Management LLC boosted its position in Praxis Precision Medicines by 51.5% in the 3rd quarter. Rafferty Asset Management LLC now owns 37,573 shares of the company’s stock valued at $1,991,000 after buying an additional 12,768 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in Praxis Precision Medicines in the 4th quarter valued at $977,000. Finally, HighVista Strategies LLC boosted its position in Praxis Precision Medicines by 41.2% in the 3rd quarter. HighVista Strategies LLC now owns 95,002 shares of the company’s stock valued at $5,035,000 after buying an additional 27,714 shares during the last quarter. 67.84% of the stock is currently owned by institutional investors.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.